Your browser is no longer supported. Please, upgrade your browser.
NXTM NxStage Medical, Inc. daily Stock Chart
NxStage Medical, Inc.
Index- P/E- EPS (ttm)-0.08 Insider Own2.10% Shs Outstand66.68M Perf Week-
Market Cap- Forward P/E- EPS next Y0.19 Insider Trans- Shs Float57.67M Perf Month-
Income- PEG- EPS next Q0.02 Inst Own91.91% Short Float9.18% Perf Quarter-
Sales425.99M P/S- EPS this Y90.90% Inst Trans- Short Ratio- Perf Half Y-
Book/sh3.38 P/B- EPS next Y1050.00% ROA- Target Price30.00 Perf Year-
Cash/sh- P/C- EPS next 5Y20.00% ROE- 52W Range- - - Perf YTD-
Dividend- P/FCF- EPS past 5Y- ROI- 52W High- Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low- ATR-
Employees3800 Current Ratio- Sales Q/Q11.10% Oper. Margin- RSI (14)- Volatility- -
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume- Prev Close-
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume- Price-
Recom3.00 SMA20- SMA50- SMA200- Volume0 Change-
Feb-22-19 06:35AM  FMC wraps up $2 bln acquisition of NxStage Reuters
Feb-20-19 04:00PM  Deals of the day-Mergers and acquisitions Reuters
02:16PM  Fresenius Medical Care AG & Co. (FMS) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:51AM  FMC expects NxStage deal to close in next couple of days Reuters
Feb-19-19 08:36PM  U.S. approves Fresenius purchase of NxStage Reuters
Jan-31-19 08:51AM  4 Healthcare Stocks Likely to Beat Estimates in Q4 Zacks
Jan-29-19 08:38AM  FMC extends deadline for NxStage deal until Aug. 6 due to U.S. government shutdown Reuters
Jan-28-19 07:45AM  Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-17-19 09:38AM  4 Medical Product Stocks Likely to Top Q4 Earnings Estimates Zacks
Dec-09-18 09:20AM  Is NxStage Medical, Inc. (NXTM) A Good Stock To Buy? Insider Monkey
NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.